| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Science Officer | Chief Scientific Officer
1 company
Eilon D. Kirson last filed a Form 4 in February 2019, as Chief Science Officer at NVCR. From December 2016 to February 2019, the filings on record show 0 open-market purchases and 11 sales. Eilon D. Kirson's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 152,408 shares of NVCR. The NVCR filings lean toward selling, a net 834,249 shares.
Shares as reported in the last Form 4 for each company; the most recent is from February 2019. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2017 | NVCR Novocure Ltd | Chief Science Officer | Sell | 20,956 | $15.03 | $315,053.39 | -6.3% |